Coronary Artery Disease
Conditions
Brief summary
The investigators would like to investigate whether clopidogrel will help lower the level of harmful markers in patients with coronary artery disease, and at the same time will help increase the cells that are useful in repairing the damaged blood vessels. The investigators will give half of the patients clopidogrel and the other half a sugar pill, placebo, and check the levels of these markers and helpful cells in each group. At the same time the investigators will check how well these patient's blood vessels work using ultrasound imaging of the forearm to see how blood vessels relax and tonometry to see how stiff the patient's blood vessels are. After 6 weeks of drug therapy, the patients will switch to the other drug and these same tests will be performed after an additional 6 weeks of therapy. The drug taken by the patient will not be known to the patient or the researchers. The patients will continue on their prescribed medical therapy during the duration of the 12 week study.
Detailed description
Blockages in the blood vessels of the heart are caused by atherosclerosis. Atherosclerosis is the main cause for chest pain and heart attacks. Gradual narrowing of the vessels of the heart caused by blockages causes chronic symptoms, such as chest pain. Those with these findings often have a cardiac catheterization to detect these blockages. Additionally these patients may have an angioplasty or stent placed to help relieve these symptoms. With this angioplasty/stent procedure, patients are placed on the drug clopidogrel to help prevent clots from forming and narrowing of the blood vessels. Clopidogrel is a blood thinner that prevents clots from forming similar to an aspirin, but is more powerful and effective. Markers, or substances, have been identified that cause worsening of the blockages in the blood vessels of the heart. Many of these substances have been shown to decrease with the use of clopidogrel. This occurs separately from clopidogrel's ability to prevent clots. Endothelial progenitor cells, or EPCs, come mostly from the bone marrow and is helpful in repairing damage to the lining of the blood vessels of the heart. The EPCs help balance out the damage incurred in the blood vessels from those harmful markers. Several other drugs commonly used in heart disease have recently been shown to improve EPCs function. With this in mind, it is important to understand more of clopidogrel's function. A decrease in markers that cause worsening of the blockages, and an increase in the number of cells that will help repair damaged blood vessels of the heart is important in avoiding future chest pain and heart attacks. This may be how clopidogrel is currently protecting patients from developing new blockages. The investigators would like to investigate whether clopidogrel will help lower the level of harmful markers in patients with coronary artery disease, and at the same time will help increase the cells that are useful in repairing the damaged blood vessels. The investigators will give half of the patients clopidogrel and the other half a sugar pill, placebo, and check the levels of these markers and helpful cells in each group. At the same time the investigators will check how well these patient's blood vessels work using ultrasound imaging of the forearm to see how blood vessels relax and tonometry to see how stiff the patient's blood vessels are. After 6 weeks of drug therapy, the patients will switch to the other drug and these same tests will be performed after an additional 6 weeks of therapy. The drug taken by the patient will not be known to the patient or the researchers. The patients will continue on their prescribed medical therapy during the duration of the 12 week study.
Interventions
DRUGClopidogrel
Clopidogrel 75 mg PO qday for 6 weeks
DRUGPlacebo
Placebo PO qday for 6 weeks
Sponsors
Emory University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male or females without child bearing potential aged 21-80 years * Known coronary artery disease by angiogram or documented myocardial infarction. * Able to provide written informed consent
Exclusion criteria
* Treated with clopidogrel or ticlodipine in the previous 3 months * Age \< 21 or \>80 years * Premenopausal females with potential for pregnancy * Allergy to clopidogrel or aspirin * Initiation or change in dose of any concomitant medical therapy within 2 months before the study * Uncontrolled hypertension with BP\>180 mmHg systolic and \>120 mmHg diastolic * Treated with coumadin therapy * Intolerance or allergy to statins * Acute infection in previous 4 weeks * History of substance abuse * Uninterpretable PAT test * Current neoplasm * Chronic renal failure \[creatinine \> 2.5 mg/dL\] or liver failure (Liver enzymes \>2X normal) * Acute coronary syndrome, heart failure, CVA, coronary intervention within 3 months * Known aortic stenosis, hypertrophic cardiomyopathy, symptomatic heart failure. * Inability to give informed consent * Inability to return to Emory for follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Flow-mediated Dilation (FMD) | Baseline, Week 12 | Flow-mediated dilation (FMD) collected by an ultrasound and is measured by the percent change in diameter of the brachial artery from baseline to 12 weeks. |
| Nitroglycerin-mediated Vasodilation | Baseline, Week 12 | Nitroglycerin (NTG)-mediated vasodilation was measured after 0.4 mg of NTG was administered sublingually. Brachial artery images were obtained via ultrasound after three minutes of NTG administration. Measurements from the twelve frames will be averaged to calculate the percent change in diameter of the brachial artery from baseline to 12 weeks. |
| Endothelial Progenitor Cells (EPCs) | Week 12 | The circulating progenitor-enriched population of cells was measured by the expression of surface antigens using direct flow cytometry for CD34+, CD34+/CD133+, CD34+/ VEGF2R+ and CD34+/CD133+/VEGF2R+ |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulse Wave Velocity (PWV) | Week 12 | PWV was measured between the carotid and femoral arteries using the SphygmoCor device. Pressure waveforms at the carotid and femoral arteries were acquired using EKG gating. Velocity (distance per time in seconds) was calculated using the foot-to-foot method and the distance between the sites was measured manually. |
| Inflammatory Marker CD40 Ligand | Week 12 | CD40 ligand levels were measured. The level of CD40 ligand were measured using the Flurokine MultiAnalyte profiling (MAP) Human Base Kit B. |
| Oxidative Stress Markers | Week 12 | Oxidative stress was measured by using liquid chromatography to collect plasma cystine, cysteine, gluthione, and oxidized glutathione levels. |
| Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP) | Week 12 | High-sensitivity C-reactive protein (hsCRP) was measured. The hsCRP levels were measured by Dade Behring nephelometry. |
Countries
United States
Participant flow
Recruitment details
Patients recruited from clinic sites at Emory University Hospital, Crawford Long Hospital, Grady Memorial Hospital and VA Medical Center between January 2008 through December 2008.
Participants by arm
| Arm | Count |
|---|---|
| All Subjects The subjects received clopidogrel 75 mg or placebo PO qd for the first 6 weeks then were switched to receive either placebo or clopidogrel 75 mg PO qd therapy for an additional 6 weeks without any wash out period in between. | 41 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Intervention (6 Weeks) | Lost to Follow-up | 1 | 0 |
| First Intervention (6 Weeks) | Physician Decision | 0 | 1 |
| First Intervention (6 Weeks) | Withdrawal by Subject | 2 | 3 |
Baseline characteristics
| Characteristic | All Subjects |
|---|---|
| Age, Continuous | 63 years STANDARD_DEVIATION 1.5 |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 48 | 0 / 48 |
| serious Total, serious adverse events | 0 / 48 | 0 / 48 |
Outcome results
Primary
Endothelial Progenitor Cells (EPCs)
The circulating progenitor-enriched population of cells was measured by the expression of surface antigens using direct flow cytometry for CD34+, CD34+/CD133+, CD34+/ VEGF2R+ and CD34+/CD133+/VEGF2R+
Time frame: Week 12
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Clopridogrel | Endothelial Progenitor Cells (EPCs) | CD34+ | 1.46 cells/µL | Standard Error 0.16 |
| Clopridogrel | Endothelial Progenitor Cells (EPCs) | CD34+/133+ | 0.68 cells/µL | Standard Error 0.07 |
| Clopridogrel | Endothelial Progenitor Cells (EPCs) | CD34+/VEGF2R+ | 0.08 cells/µL | Standard Error 0.03 |
| Clopridogrel | Endothelial Progenitor Cells (EPCs) | CD34+/CD133+/VEGF2R+ | 0.03 cells/µL | Standard Error 0.009 |
| Placebo | Endothelial Progenitor Cells (EPCs) | CD34+/CD133+/VEGF2R+ | 0.03 cells/µL | Standard Error 0.008 |
| Placebo | Endothelial Progenitor Cells (EPCs) | CD34+ | 1.54 cells/µL | Standard Error 0.21 |
| Placebo | Endothelial Progenitor Cells (EPCs) | CD34+/VEGF2R+ | 0.09 cells/µL | Standard Error 0.02 |
| Placebo | Endothelial Progenitor Cells (EPCs) | CD34+/133+ | 0.75 cells/µL | Standard Error 0.16 |
Primary
Flow-mediated Dilation (FMD)
Flow-mediated dilation (FMD) collected by an ultrasound and is measured by the percent change in diameter of the brachial artery from baseline to 12 weeks.
Time frame: Baseline, Week 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Clopridogrel | Flow-mediated Dilation (FMD) | 4.89 percent change in diameter | Standard Error 0.59 |
| Placebo | Flow-mediated Dilation (FMD) | 4.81 percent change in diameter | Standard Error 0.59 |
Primary
Nitroglycerin-mediated Vasodilation
Nitroglycerin (NTG)-mediated vasodilation was measured after 0.4 mg of NTG was administered sublingually. Brachial artery images were obtained via ultrasound after three minutes of NTG administration. Measurements from the twelve frames will be averaged to calculate the percent change in diameter of the brachial artery from baseline to 12 weeks.
Time frame: Baseline, Week 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Clopridogrel | Nitroglycerin-mediated Vasodilation | 19.31 percent change in diameter | Standard Error 1.49 |
| Placebo | Nitroglycerin-mediated Vasodilation | 17.10 percent change in diameter | Standard Error 1.51 |
Secondary
Inflammatory Marker CD40 Ligand
CD40 ligand levels were measured. The level of CD40 ligand were measured using the Flurokine MultiAnalyte profiling (MAP) Human Base Kit B.
Time frame: Week 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Clopridogrel | Inflammatory Marker CD40 Ligand | 1202.21 pg/mL | Standard Error 318.35 |
| Placebo | Inflammatory Marker CD40 Ligand | 2169.32 pg/mL | Standard Error 318.35 |
Secondary
Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP)
High-sensitivity C-reactive protein (hsCRP) was measured. The hsCRP levels were measured by Dade Behring nephelometry.
Time frame: Week 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Clopridogrel | Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP) | 5.98 mg/L | Standard Error 1.95 |
| Placebo | Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP) | 4.31 mg/L | Standard Error 1.95 |
Secondary
Oxidative Stress Markers
Oxidative stress was measured by using liquid chromatography to collect plasma cystine, cysteine, gluthione, and oxidized glutathione levels.
Time frame: Week 12
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Clopridogrel | Oxidative Stress Markers | Cystine | 105.25 µM | Standard Error 7.36 |
| Clopridogrel | Oxidative Stress Markers | Cysteine | 13.71 µM | Standard Error 0.9 |
| Clopridogrel | Oxidative Stress Markers | Oxidized glutathione | 0.08 µM | Standard Error 0.06 |
| Clopridogrel | Oxidative Stress Markers | Glutathione | 1.52 µM | Standard Error 0.17 |
| Placebo | Oxidative Stress Markers | Oxidized glutathione | 0.19 µM | Standard Error 0.06 |
| Placebo | Oxidative Stress Markers | Cystine | 102.39 µM | Standard Error 7.29 |
| Placebo | Oxidative Stress Markers | Cysteine | 14.75 µM | Standard Error 0.89 |
| Placebo | Oxidative Stress Markers | Glutathione | 1.71 µM | Standard Error 0.17 |
Secondary
Pulse Wave Velocity (PWV)
PWV was measured between the carotid and femoral arteries using the SphygmoCor device. Pressure waveforms at the carotid and femoral arteries were acquired using EKG gating. Velocity (distance per time in seconds) was calculated using the foot-to-foot method and the distance between the sites was measured manually.
Time frame: Week 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Clopridogrel | Pulse Wave Velocity (PWV) | 8.77 m/s | Standard Error 0.45 |
| Placebo | Pulse Wave Velocity (PWV) | 9.044 m/s | Standard Error 0.45 |